glp-1/gip/glucagon triple agonist name LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept GIPR/GLP-1R dual agonist therapies for

This study explored whether GLP-1RA use in T2DM was associated with a reduction in CRC risk

1 This article explores the emerging role of GLP-1RAs, originally developed for diabetes and obesity, in treating alcohol addiction

Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia

The only apparent difference was an increase in diastolic blood pressure before the beginning of the placebo treatment in patients who received dulaglutide first

Nelsons treatment triggered early menopause, which caused the former dancer to gain weight and struggle to lose it

Jardiance functions as an SGLT2 inhibitor, which means it blocks glucose reabsorption in your kidneys, allowing excess glucose to be eliminated through urine